A new understanding of antibiotic resistance in nosocomial infections: Part 2 - Lessons for the future

British Journal of Intensive Care

Volumn 15, Issue 2, 2005, Pages 62-71

  Masterton, R G ^a,b  

^a NHS AYRSHIRE AND ARRAN   (United Kingdom)

^b CROSSHOUSE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CARBAPENEM; CEPHALOSPORIN; CIPROFLOXACIN; GENTAMICIN; METICILLIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIUM ISOLATE; CHROMOSOME MUTATION; CROSS RESISTANCE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION RISK; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL ACTIVITY; PATIENT CARE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 24644524137     PISSN: 09617930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Cassell GH, Mekalanos J. Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance. JAMA 2001; 286: 601-605.
2. Jarvis WR. Infection control and changing health-care delivery systems. Emerg Infect Dis 2001; 7:170-173.
3. Jones RN. Resistance patterns among nosocomial pathogens. Trends over the past few years. Chest 2001; 119: 397S-404S.
4. Weinstein RA. Nosocomial infection update. Emerg Infect Dis 1998; 4: 416-420.
5. Clark NM, Hershberger E, Zervosc MJ, Lynch JP 3rd. Antimicrobial resistance among Gram-positive organisms in the intensive care unit. Curr Opin Crit Care 2003; 9: 403-412.
6. Clark NM, Patterson J, Lynch JP 3rd. Antimicrobial resistance among Gram-negative organisms in the intensive care unit. Curr Opin Crit Care 2003; 9: 413-423.
7. Kollef M. Treating hospital infections right, first time. Eur J Hosp Pharm 2003; 2: 46-47.
8. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7: 178-182.
9. Charlebois ED, Perdreau-Remington F, Kreiswirth B et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004; 39: 47-54.
10. Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 2004; 39: 971-979.
11. Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 2001; 9: 486-493.
12. Layton MC, Hierholzer WJ Jr, Patterson JE. The evolving epidemiology of methicillin-resistant Staphylococcus aureus at a university hospital. Infect Control Hosp Epidemiol 1995; 16: 12-17.
13. Vandenesch F, Etienne J. How to prevent transmission of MRSA in the open community? Euro Surveill 2004; 9: 1-2.
14. Davis KA, Stewart JJ, Crouch HK, Florez CE, Hospenthal DR. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 2004; 39: 776-782.
15. Roghmann MC, Siddiqui A, Plaisance K, Standiford H. MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers. J Hosp Infect 2001; 47: 98103.
16. Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003; 36: 281-285.
17. Simor AE. Containing methicillin-resistant S. aureus. Surveillance, control, and treatment methods. Postgrad Med 2001; 110: 43-48.
18. Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290: 2976-2984.
19. Jernigan JA, Damn R. Methicillin resistant Staphylococcus aureus in the community: infection control strategies. Meet the Experts session at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, USA, 30 October-2 November 2004.
20. Vandenesch F, Naimi T, Enright MC et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003; 9: 978-984.
21. Solberg CO. Spread of Staphylococcus aureus in hospitals: causes and prevention. Scand J Infect Dis 2000; 32: 587-595.
22. Sanford MD, Widmer AF, Bale MJ, Jones RN, Wenzel RP. Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1994; 19: 1123-1128.
23. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36: 131-139.
24. Smith TL, Pearson ML, Wilcox KR et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493-501.
25. Sievert DM, Boulton ML, Stoltman G et al. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Mor Mortal Wkly Rep 2002; 51: 565-567.
26. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 2002; 56: 657-675.
27. Livermore DM. The threat from the pink corner. Ann Med 2003;35: 226-234.
28. Shah AA, Hasan F, Ahmed S, Hameed A. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases. Res Microbiol 2004; 155: 409-421.
29. Jones RN, Mathai D, Rhomberg PR et al. A comparison of the antimicrobial activity of meropenem and select anti microbials tested against multi-drug resistant Gram negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC programme in India. Int J Antimicrob Agents 2002; 20: 426-431.
30. Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis 2001; 41: 183-189.
31. Masterton R, Turner P. The UK MYSTIC surveillance programme confirms the sustained activity of the carbapenems over a 6-year period (1997-2002). Int J Antimicrob Agents (in press).
32. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999; 20: 303-316.
33. Rice LB. Controlling antibiotic resistance in the ICU: different bacteria, different strategies. Cleve Clin J Med 2003; 70: 793-800.
34. Paterson DL, Ko WC, Von Gottberg AV et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-2212.
35. Paterson DL, Ko W-C, Von Gottberg A et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis 2004; 39: 31-37.
36. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38 Suppl 4: S341-S345.
37. Colodner R, Rock W, Chazan B et al. Risk factors for the development of extended-spectrum beta-lactamase-produdng bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004; 23: 163-167.
38. Rodríguez-Baño J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-1094.
39. Fridkin SK, Hill HA, Volkova NV et al. Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002; 8: 697-701.
40. Jones ME, Draghi DC, Thornsberry C et al. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004; 3: 14.
41. Neuhauser MM, Weinstein RA, Rydman R et al. Antibiotic resistance among Gram-negative bacilli in US intensive care units. JAMA 2003; 289: 885-888.
42. Thomson CJ. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10-year perspective. J Antimicrob Chemother 1999; 43 (Suppl A): 31-40.
43. Masterton RG. Ciprofloxacin resistance - 'early-warning' signs from the MYSTIC surveillance programme? J Antimicrob Chemother 2002; 49: 218-220.
44. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002; 2: 530-638.
45. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase production. J Antimicrob Chemother 2003; 51: 1109-1117.
46. Schmitz F-J, Higgins PG, Mayer S, Fluit AC, Dalhoff A. Activity of quinolones against Gram-positive cocci: mechanisms of drug action and bacterial resistance. Eur J Clin Microbiol Infect Dis 2002; 21: 647-659.
47. Jones RN, Pfaller MA. Bacterial resistance: a worldwide problem. Diagn Microbiol Infect Dis 1998; 31: 379-388.
48. Kollef MH. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. Respir Care 2004; 49: 1530-1541.
49. Motyl M, Mixson L, Friedland IR, Woods GL. Ertapenem: A parenteral, long-acting carbapenem. Clinical Microbiology Newsletter 2003; 25: 89-95.
50. Garcia-Rodriguez JA, Jones RN, and the MYSTIC Programme Study Group. Antimicrobial resistance in Gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme. J Chemother 2002; 14: 25-32.
51. Harris AD, Smith D, Johnson JA et al. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002; 34: 340-345.
52. Lepper PM, Grusa E, Reichl H et al. Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 2920-2925.
53. Cottagnoud P. Cellular and molecular aspects of drugs of the future: meropenem. Cell Mol Life Sci 2002; 59: 1928-1933.
54. Livermore DM, Woodfbrd N. Carbapenemases: a problem waiting to happen? Curr Opin Microbiol 2000; 3: 489-495.
55. Mokaddas EM, Sanyal SC. Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperatillin/tazobactam. J Chemother 1999; 11: 93-96.
56. Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Investig Drugs 2002; 3: 218-224.
57. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134: 298-314.
58. Kollef MH. Appropriate empirical antibacterial therapy for nosocomial infections. Getting it right the first time. Drugs 2003; 63: 2157-2168.
59. Blot S, Vandewoude K, Hoste E et al. Absence of excess mortality in critically ill patients with nosocomial Escherichia coli bacteremia. Control Hosp Epidemiol 2003; 24: 912-915.
60. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31: 2742-2751.
61. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36: 1418-1423.
62. Rello J, Gallego M, Mariscal D et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156: 196-200.
63. Masterton R, Drusano G, Paterson DL, Park G. Appropriate antimicrobial treatment in nosocomial infections - the clinical challenges. J Hosp Infect 2003; 56: 1-12.
64. Paterson DL, Rice LB. Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 2003; 36: 1006-1012.
65. Sandiumenge A, Diaz E, Bodíí, Rello J. Therapy of ventilator-associated penumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive Care Med 2003; 29: 876-883.
66. Shlaes DM, Gerding DN, John JR, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997; 18: 275-291.
67. Vincent J-L. Nosocomial infections in adult intensive-care units. Lancet 2003; 361: 2068-2077.
68. Warren DK, Fraser VJ. Infection control measures to limit antimicrobial resistance. Crit Care Med 2001; 29 (Suppl): N128-N134.
69. Iregui M, Ward S, Sherman G et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-268.
70. Chastre J, Wolff M, Fagon JY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290: 2588-2598.
71. Goldmann DA, Weinstein RA, Wenzel RP et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996; 275: 234-240.
72. Kollef MH. Optimizing antibiotic therapy in the intensive care unit setting. Crit Care 2001; 5: 189-195.
73. Poretta A, Giuliani L, Vegni FE, Larosa M, Privitera G, and the INF-NOS Study Group. Prevalence and patterns of antibiotic prescribing in Italian hospitals. Infection 2003; 31 (Suppl 2): 16-21.
74. Masterton RG. Antibiotic cycling: more than it might seem? J Antimicrob Chemother 2005; 55: 1-5.
75. Niederman MS. Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU? Am J Respir Crit Care Med 1997; 156: 1029-1031.
76. Masterton RG, Kuti JL, Turner PJ, Nicolau DP. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother 2005; 55: 71-77.
77. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004; 26: 1187-1198.
78. Srinivan A, Song X, Richards A et al. A survey of knowledge, attitude, and beliefs of house staff physicians from various specialties concerning antimicrobial use and resistance. Arch Intern Med 2004; 164: 1451-1456.
79. Lazzari S, Allegranzi B, Concia E. Malring hospitals safer: the need for a global strategy for infection control in health care settings. World Hosp Health Serv 2004; 40: 36-42.